Updates are available Correction dated 2025-10-10
Click to view Correction: https://doi.org/10.1038/s43018-025-01064-4
-
Authors
Chin, Kar Wei
Chong, Wan-Qin
Goh, Boon Cher https://orcid.org/0000-0002-4107-102X
Ma, Brigette B. Y. https://orcid.org/0000-0003-4802-1102
- License Information
-
More Information
Article History
First Online: 19 September 2025
Change Date: 10 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-025-01064-4
Competing interests
: B.C.G. declares research support from MSD, Taiho, Gilead and Adagene. B.C.G. is the principal investigator for clinical trials with Bayer healthcare, Alx pharmaceuticals, Boehinger Ingelheim, Novartis, Pfizer and MSD. B.B.Y.M. is an advisory board member and receives speaker’s honoraria from Bristol Myers Squibb, Merck Serono, MSD and Novartis, and is a consultant for Y-Biologics. W.-Q.C. declares research funding from MSD, honoraria from MSD and Ipsen, consulting fees from Merck, Diethelm, KellerSiberHegner and Junshi Biosciences. K.W.C. declares no competing interests.
